How many Cochlear shares do I need to buy for $10,000 of passive income?

Working out how many Cochlear Ltd (ASX: COH) shares you need for $10,000 of passive income is simple maths, but the answer might catch you off guard.

Cochlear is the world’s leading maker of implantable hearing solutions, holding around 60% of the global cochlear implant market.

For years, the company was a dependable compounder that quietly rewarded patient shareholders.

The past 12 months, however, have tested even its most loyal investors.

The dividend maths for Cochlear shares

Cochlear pays two dividends to shareholders each year.

Lately, those payments have added up to an annual dividend of $4.30 per share.

The most recent interim dividend of $2.15 was franked at 85%, which adds a further tax benefit for many holders.

To generate $10,000 in annual passive income, including franking credits, the calculation is straightforward.

You simply divide $10,000 by the grossed-up dividend of about $5.87 (the $4.30 cash payout plus roughly $1.57 in franking credits).

That works out to roughly 1,705 Cochlear shares.

At current share prices of around $118, those shares would set you back close to $201,190.

That is a serious amount of capital for most everyday investors to commit, and it is also a reminder that Cochlear has never really been an income stock at heart.

At current prices, the shares offer a gross dividend yield of about 3.6%, although franking credits sweeten that headline return a little further at tax time.

Why have Cochlear shares fallen so far?

The dividend is only half the story here.

Cochlear shares have dropped heavily over the past year, one of the reasons why Cochlear’s dividend yield looks unusually generous now.

The stock currently trades far below its 52-week high of $319.56, largely due to a run of disappointing news from the company itself.

Recent earnings in focus

Cochlear reported its half-year results for the six months to 31 December 2025 back in February.

In these results, sales revenue came in at about $1.17 billion, broadly flat on the prior corresponding period. Statutory net profit fell a nasty 21% to $161.5 million, and underlying net profit slipped 9% to $195 million.

The weaker result was driven largely by the costly rollout of the new Nexa implant system, while competitive discounting from rivals chipped away at market share.

Management chose to hold the interim dividend steady rather than lift it, a call that speaks volumes about the year ahead.

Investors will get their next major update when Cochlear reports its full-year FY26 results on 18 August 2026.

Are Cochlear shares worth it for the income?

That is the real question for income-focused investors.

Cochlear is a high-quality business with a wide competitive moat, but its dividend yield is modest next to the ASX banks or Telstra Group Ltd (ASX: TLS).

An investor chasing pure income could reach $10,000 with far less capital elsewhere.

The appeal of Cochlear shares has always been growth, not yield, and anyone buying today is really paying for a long-term recovery story.

In other words, the dividend is a bonus, not the main event.

Foolish Takeaway

You would need roughly 1,705 Cochlear shares to earn $10,000 in annual passive income once franking credits are included.

At current prices, that means an outlay of close to $201,000.

For most investors, Cochlear shares make more sense as a growth holding than a pure income one.

On the growth front, Cochlear’s looming FY26 result will tell us whether the recovery is finally on track.

Until then, the passive income case remains an expensive one to make.

The post How many Cochlear shares do I need to buy for $10,000 of passive income? appeared first on The Motley Fool Australia.

More reading

• I’d listen to Warren Buffett and buy cheap ASX shares
• Down 50%+: Are these ASX healthcare shares finally worth buying?
• Here’s why I’d buy and hold CSL and Cochlear shares for 10 years
• Cochlear shares have bounced 16%. Should you buy, hold, or sell now?
• 10 fantastic ASX shares to buy for FY27

Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.